Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

China flag China · Delayed Price · Currency is CNY
28.54
-0.74 (-2.53%)
At close: Mar 6, 2026
Market Cap11.58B +151.5%
Revenue (ttm)704.16M +33.7%
Net Income22.23M
EPS0.05
Shares Out405.71M
PE Ratio520.83
Forward PE196.83
Dividendn/a
Ex-Dividend Daten/a
Volume7,817,871
Average Volume5,798,375
Open29.68
Previous Close29.28
Day's Range28.45 - 29.68
52-Week Range12.45 - 34.68
Beta0.51
RSI61.03
Earnings DateMar 20, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 463
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688319
Full Company Profile

Financial Performance

In 2024, SHA:688319's revenue was 588.86 million, an increase of 18.69% compared to the previous year's 496.12 million. Earnings were 20.76 million, an increase of 18.24%.

Financial Statements